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MeCP2	 (orange)	are	bound	 to	acceptor	and	donor	beads	via	antibodies	 that	have	
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TBL1X/TBL1XR1,	 which	 forms	 the	 scaffold	 of	 NCoR/SMRT	 co-repressor	 complex.	 Patients	
with	 RTT	 show	 no	 signs	 of	 neuronal	 death,	 although	 they	 have	 abnormal	 neuronal	
morphology,	 indicating	 that	 it	 is	 a	 neurodevelopmental	 rather	 than	 a	 neurodegenerative	







the	 interaction	 between	MeCP2	 and	 TBL1XR1.	 I	 have	 solved	 the	 structure	 of	MeCP2	NID	
bound	 to	 TBL1XR1	WD40	 domain.	 I	 show	 that	 a	 small	 region	 of	 the	MeCP2	 NID	 makes	
extensive	contacts	with	TBL1XR1,	and	that	these	contacts	are	mediated	primarily	by	MeCP2	
residues	known	to	be	mutated	in	RTT.	I	also	measured	the	affinities	between	TBL1XR1	and	
MeCP2-derived	 peptides	 using	 fluorescence	 anisotropy	 and	 surface	 plasmon	 resonance	
assays.	I	determined	the	affinity	between	MeCP2	NID	peptide	and	TBL1XR1	to	be	around	10-
20	µM,	and	show	that	mutations	in	either	MeCP2	or	TBL1XR1	can	abolish	this	interaction.		
Taken	together,	 these	data	strongly	suggest	 that	 the	abolition	of	 the	 interaction	between	
MeCP2	NID	and	TBL1XR1	WD40	domain	is	sufficient	to	cause	RTT.	This	knowledge	can	help	










































































Rett	 syndrome	 (RTT)	 is	 an	 X-linked	 neurological	 disorder	 characterised	 by	 initial	 normal	
development	for	about	6-9	months,	followed	by	gradual	loss	of	cognitive	and	psychomotor	
skills.	Symptoms	of	RTT	include	seizures,	loss	of	purposeful	hand	movement,	breath	holding	













altered	neuronal	morphology,	 including	 smaller	 soma	and	a	 reduced	number	of	dendritic	


























some	 unknown	 factor	 could	 have	 caused	 phenotypic	 variation	 in	 the	 presence	 of	 well-
characterised	RTT	mutations.	Other	mutations	in	MeCP2	that	do	not	cause	RTT	have	been	
proposed	to	cause	X-linked	mental	retardation	(Couvert	et	al.,	2001),	and	potentially	global	







However,	 approximately	 95%	 of	 patients	 with	 RTT	 have	 mutations	 in	 the	 MeCP2	 gene.	












gene	 transcription	 are	 thought	 to	 be	 influenced	 by	 DNA	 methylation	 and	 histone	
modifications,	 referred	 to	 as	 the	 epigenetic	 code	 (Turner,	 2007).	 Control	 over	 gene	
transcription	is	essential	for	the	development	and	survival	of	an	organism.	A	predominant	
DNA	modification	that	is	heritable	between	cell	divisions	is	5-methylation	of	cytosines	(5mC)	
in	 CG	 dinucleotide	 context.	 This	 modification	 is	 added	 by	 de	 novo	 methyltransferases	












be	 required	 to	 reinforce	 silencing,	 as	 most	 CGIs	 that	 are	 methylated	 are	 already	








Kaiso	protein	 families.	Members	 of	 the	MBD	 family	 are	MBD1,	MBD2,	MBD3,	MBD4	and	
MeCP2,	 which	 all	 possess	 homologous	 methyl-CpG-binding	 domains	 (MBDs).	 DNA	
methylation	has	a	multifaceted	role.	Methylation	of	DNA	leads	to	transcriptional	repression	
through	 either	 direct	 blocking	 of	 transcription	 factors,	 or	 through	 the	 exclusion	 of	
transcription	 factors	 by	 the	methyl-DNA	binding	 proteins.	 The	 latter	 can,	 in	 turn,	 lead	 to	






Removal	 of	 DNA	 methylation	 occurs	 through	 successive	 oxidation	 of	 the	 5mC	 into	 5-




part	 of	 the	 epigenetic	 code	 as	 these	 modifications	 are	 not	 distributed	 randomly	 in	 the	
genome	and	at	least	5hmC	is	a	stable	mark.	However	sequencing	of	these	marks	is	technically	


















lysine	 residues	 and	 weakens	 DNA-histone	 interactions	 (Hong	 et	 al.,	 1993).	 This	 makes	
chromatin	 more	 accessible	 and	 is	 associated	 with	 transcriptional	 activation,	 either	 by	
facilitating	transcription	factor	binding	through	more	accessible	chromatin,	or	recruitment	of	
transcriptional	 coactivators.	Acetylated	histones	 are	 recognised	by	 a	number	of	 domains,	
















11,	 has	 little	 sequence	 homology	 to	 either	 RPD3	 or	 HDA1.	 Class	 I	 HDACs	 are	 almost	























Methylation	 occurs	 on	 lysine	 and	 arginine	 residues,	 and	 is	 carried	 out	 by	 histone	 lysine	





asymmetrical	 (Figure	 1.2.3).	 The	 role	 of	 methylation	 is	 more	 complex,	 as	 for	 example	
monomethylation	of	H3K9	and	H3K27	coincides	with	active	genes,	while	trimethylation	of	
H3K9	and	H3K27	are	associated	with	repressed	genes	(Barski	et	al.,	2007).	Methylation	of	
lysines	 is	 recognised	 by,	 for	 example,	 chromodomains,	 PHD	 finger	 domains,	 and	 Tudor	
domains,	 the	 latter	 being	 also	 involved	 in	 binding	 to	 methylated	 arginines	 (Gayatri	 and	
Bedford,	 2014).	 In	 addition,	 some	WD40	 domains	 are	 involved	 in	 binding	 to	methylated	
histones,	as	described	in	section	1.4.1.	
While	the	number	of	different	modifiable	histone	residues	is	high,	further	combinations	can	
occur	 through	 histones	 modified	 with	 more	 than	 one	 chemical	 mark,	 where	 different	
modifications	can	act	antagonistically.	An	example	of	this	is	the	binding	of	HP1	to	H3K9me3,	
where	phosphorylation	of	S10	on	histone	3	(H3pS10)	abolishes	the	binding	of	HP1	(Fischle	et	
al.,	 2005).	 In	 this	 light,	 due	 to	 the	 sheer	 amount	 of	 possible	 combinations	 of	 histone	
modifications,	 arising	 from	 the	 number	 of	 modifications	 plus	 the	 number	 of	 modifiable	
residues	on	histone	tails,	the	histone	code	has	not	yet	been	fully	elucidated.	
In	this	thesis	I	will	discuss	a	member	of	the	methyl-CpG-binding	protein	family,	MeCP2,	which	



























































(Lyst	 and	 Bird,	 2015).	 As	 MeCP2	 is	 largely	 unstructured,	 and	 therefore	 the	 interdomain	
regions	are	 likely	not	required	for	the	stability	of	the	three-dimensional	fold,	 it	 is	possible	
that	the	expansion	of	the	protein	is	neutral	and	that	these	regions	have	no	true	functional	








outlined	with	a	 red	box.	 Species	 are	 as	 follows:	Homo	 sapiens	 –	human,	Mus	musculus	 –	house	






proteins	 identified	 were	 associated	 with	 brain	 or	 neuronal	 function.	 Furthermore,	






DNA.	 A	 crystal	 structure	 of	 the	 MeCP2	MBD	 bound	 to	 methylated	 DNA	 shows	 that	 the	
residues	 in	 the	MBD	 (R111	 and	 R133)	 do	 not	 recognise	 the	methylated	 cytosines	 (5mC)	
directly,	but	rather	through	ordered	water	molecules	in	the	major	groove	(Figure	1.3.4)	(Ho	













density	 (Skene	et	al.,	2010).	This	 is	 supported	by	an	observation	 that	while	 the	affinity	of	
MeCP2	 for	 unmethylated	DNA	 is	 only	 three	 times	 lower	 than	monomethylated	DNA,	 the	
presence	 of	multiple	 CpG	 repeats	 increases	 its	 affinity	 for	methylated	 DNA	 (Fraga	 et	 al.,	




In	 addition	 to	 5mC	 binding,	MeCP2	 also	 binds	 5-hydroxymethylcytosine	 (5hmC),	 another	
epigenetic	mark	which	 is	 enriched	 in	brain.	 The	R133C	mutation	abolishes	 the	binding	of	
MeCP2	 to	 5hmC,	 while	 retaining	 its	 ability	 to	 bind	 5mC	 (Mellen	 et	 al.,	 2012).	 MeCP2	
overexpression	decreased	the	levels	of	5hmC,	while	loss	of	MeCP2	showed	increased	levels	
of	 5hmC.	 Consistent	 with	 this	 observation,	 MeCP2	 was	 shown	 to	 be	 able	 to	 block	 TET	
enzymes	 from	 converting	 5mC	 into	 5hmC	 in	 vitro	 (Szulwach	 et	 al.,	 2011).	 Furthermore,	
MeCP2	 has	 been	 shown	 to	 bind	 preferentially	 to	 long	 genes	with	 high	mCA	 content	 and	
repress	them,	whereas	short	genes	with	low	or	high	mCA	content,	and	long	genes	with	low	
mCA	content	are	not	misregulated	 in	an	MeCP2	knockout.	 It	was	demonstrated	that	 long	
genes	 are	 more	 likely	 to	 be	 associated	 with	 neuronal	 function	 (Gabel	 et	 al.,	 2015).	










Several	missense	mutations	 in	 the	 NID	 have	 been	 shown	 to	 cause	 RTT	 (Figure	 1.3.1).	 In	

























Figure	 1.3.5.	 Schematic	 overview	 of	 NCoR/SMRT	 corepressor	 complex.	 	 TBL1X	 and/or	 TBL1XR1	
(blue)	 form	 a	 tetrameric	 scaffold	 through	 their	 LisH	 domains.	 This	 scaffold	 interacts	 with	 the	
NCoR/SMRT	(pink)	and	GPS2	(grey).	In	addition,	MeCP2	NID	(orange)	interacts	with	WD40	domain	












Recently,	 the	 effect	 of	 HDAC3	 knockout	 in	 neurons	 was	 investigated.	 Mice	 with	 HDAC3	
conditional	 knockout	 (KO)	 in	 forebrain	 neurons	 showed	 RTT-like	 symptoms	 and	
misregulation	 (both	up	and	downregulation)	of	over	300	genes,	many	of	 them	associated	


















binding	 to	 TBL1X/TBL1XR1.	 In	NID	mutations	 (example	 -	 R306C),	MeCP2	 can	bind	 to	DNA	but	 is	
unable	to	recruit	TBL1X/TBL1XR1.	
Given	 the	 roles	 of	 both	 acetylation	 and	 HDACs	 in	 regulating	 gene	 transcription,	 it	 is	






















of	 two	 alpha	 helices	 (Emes	 and	 Ponting,	 2001).	 It	 is	 involved	 in	 both	 dimerisation	 and	
tetramerisation	of	TBL1X	and	TBL1XR1.	Since	the	LisH	motif	is	conserved	between	TBL1X	and	
TBL1XR1,	 it	 is	 possible	 that	 the	 proteins	 can	 form	 dimers	 of	 homodimers,	 and	 possibly	
heterodimers,	 however	 this	 has	 not	 been	 demonstrated	 experimentally.	 The	 region	 of	
human	 TBL1X	 spanning	 residues	 1-70	 (identical	 to	mouse	 TBL1X)	 interacts	with	GPS2	 (G-
protein	pathway	Suppressor	2)	and	NCoR/SMRT	(Oberoi	et	al.,	2011).	 Interaction	of	GPS2	
with	TBL1X	is	required	to	protect	it	from	degradation	by	the	proteasome,	and	this	is	mediated	




Both	 TBL1X	 and	 TBL1XR1	 also	 interact	 with	 histone	 H4,	 and	 preferentially	 with	
hypoacetylated	 H4	 (Yoon	 et	 al.,	 2005),	 although	 this	 interaction	 has	 not	 been	 mapped.	
Whether	 the	 binding	 of	 TBL1X	 to	 hypoacetylated	 H4	 and	 the	 recruitment	 of	 HDAC3	 are	




distinct	 roles	 in	 cells	by	 interacting	with	a	different	 subset	of	nuclear	 receptors,	although	
some	overlap	exists	 (Perissi	et	al.,	2004).	A	 third	protein	called	TBL1Y	 is	present	on	 the	Y	
chromosome	which	is	unable	to	repress	promoter	activity	that	TBL1X	and	TBL1XR1	repress,	
suggesting	a	role	separate	from	both	TBL1X	and	TBL1XR1	(Yan	et	al.,	2005).	As	these	three	










As	mentioned	 earlier,	MeCP2	 has	 been	 shown	 to	 interact	with	 NCoR/SMRT	 and	 the	 RTT	
R306C	mutation	 in	MeCP2	 abolishes	 the	 nuclear	 localisation	 of	 TBL1X	 in	 ex	 vivo	 assays.	





a	 single	 amino	 acid	 (E364G)	 abolishes	 this	 interaction.	 This	 interaction,	 as	 well	 as	 the	
potential	 role	 of	 TBL1X	 and	 TBL1XR1	 in	 RTT	 syndrome	 and	 related	 intellectual	 disability	
disorders	will	 be	 discussed	 at	 length	 in	 chapter	 five.	 In	 addition	 to	 RTT,	 both	 TBL1X	 and	
TBL1XR1	are	involved	in	a	variety	of	cancers	(Daniels	et	al.,	2014,	Ramadoss	et	al.,	2011,	Garg	
and	Aggarwal,	2002).	Interestingly,	levels	of	TBL1X	and	TBL1XR1	have	been	found	to	be	both	
up-	 and	 down-regulated	 in	 different	 cancers	 (Daniels	 et	 al.,	 2014,	Wang	 et	 al.,	 2014).	 In	
support	of	this	role,	TBL1X	has	been	shown	to	be	required	for	the	recruitment	of	NF-κB,	a	
transcription	factor	that	regulates	the	expression	of	many	genes	involved	in	tumorigenesis	
(Ramadoss	 et	 al.,	 2011),	 and	 whose	 abnormal	 activation	 is	 commonly	 found	 in	 cancers	
(Perkins,	2004).	
Both	 TBL1X	 and	 TBL1XR1	 are	 involved	 in	 ligand-dependent	 nuclear	 cofactor	 exchange	 by	
recruiting	 the	 proteasome	 to	 degrade	 NCoR,	 which	 leads	 to	 binding	 of	 coactivators	 and	









They	 rarely	 occur	 on	 their	 own,	 rather	 they	 are	 frequently	 present	 in	 conjunction	 with	




part	 of	 one	 blade,	 while	 strand	 d’	 complements	 the	 beta	 sheet	 of	 a	 preceding	 blade.	
Consequently,	a	WD40	blade	consists	of	beta	strands	a-b-c-d	that	bridge	two	repeats	(Figure	
















terminus	 is	 the	 ‘d’	 strand	of	 the	C-terminal	blade,	which	completes	 the	ring	and	provides	
structural	stability,	although	that	is	not	always	the	case	as	can	be	seen,	for	example,	in	DNA-














protein-DNA	 interactions.	These	 interactions	occur	mostly	 through	 the	 top	 face,	although	
bottom	and	side	 faces	have	been	shown	to	mediate	 some	 interactions	 (Stirnimann	et	al.,	
2010).	The	variability	in	the	interactions	comes	from	these	loops	present	between	the	d-a	
and	b-c	beta	strands	on	the	top	face.	Analysis	of	WD40	domains	has	found	that	there	are	
certain	 amino	 acid	 positions	 in	 these	 blades	 and	 loops,	 called	 hotspots,	 that	 are	 often	
involved	 in	mediating	 protein-protein	 interactions	 (Wu	 et	 al.,	 2012)	 (Figure	 1.4.5).	 These	







Figure	 1.4.5.	 Structural	 representation	 of	 a	 single	 WD40	 blade.	 Residues	 that	 are	 often	 found	
mediating	protein-protein	interactions	are	labelled	R1,	R1-2,	and	D-1	(pink).	DH(S/T)W	tetrad	which	
has	been	highlighted	here	will	be	discussed	in	Chapter	5.	(Figure	taken	from	(Wu	et	al.,	2012))	





Kingston,	2008),	and	EZH2	 in	 the	case	of	EED	 (Han	et	al.,	2007).	 In	 this	way,	 these	WD40	
domains	are	able	to	link	histone	modifications	with	histone-modifying	enzymes.	In	this	light	
it	is	interesting	that	a	variety	of	point	mutations	in	TBL1XR1	WD40	domain	cause	intellectual	






affect	 the	 overall	 folding	 success,	 although	 they	 have	 an	 impact	 on	 the	 kinetics	 (Garcia-









The	 main	 aim	 of	 this	 project	 was	 to	 understand	 the	 molecular	 basis	 for	 the	 interaction	
between	MeCP2	NID	and	TBL1X/TBL1XR1,	and	consequently	understand	why	RTT	mutations	
cause	the	loss	of	binding	to	TBL1X/TBL1XR1.	This	was	achieved	by	co-crystallising	and	solving	
the	 structure	 of	 MeCP2	 NID	 and	 TBL1XR1	 using	 X-ray	 crystallography.	 In	 addition,	 the	
interaction	was	characterised	using	biophysical	and	biochemical	methods.	
In	order	to	successfully	complete	the	main	aim,	TBL1X/TBL1XR1	at	high	purity	was	required.	












The	following	chapters	 in	 this	 thesis	present	the	results	of	 these	experiments	and	answer	








Several	 constructs	 were	 cloned	 by	 Dr.	 Atlanta	 Cook	 prior	 to	 the	 start	 of	 the	 project	 for	
heterologous	expression	in	E.	coli,	listed	in	Table	2.1.1.	
Table	2.1.1.	List	of	constructs	cloned	prior	to	the	start	of	the	project	
Protein	 Construct	 Tag	 Organism	 Vector	
MeCP2	 197-339	 N-GST	 H.	sapiens	 pEC-KGC	
MeCP2	 266-339	 N-GST	 H.	sapiens	 pEC-KGC	
MeCP2	 286-339	 N-GST	 H.	sapiens	 pEC-KGC	
TBL1X	 141-527	 N-GST	 H.	sapiens	 pEC-KGC	




Protein	 Construct	 Tag	 Organism	 Vector	
TBL1X	 1-527	 N-His6x	 M.	musculus	 pFL	
TBL1X	 148-527	 N-His6x	 M.	musculus	 pFL	
TBL1X	 176-527	 N-His6x	 M.	musculus	 pFL	
TBL1XR1	 1-514	 N-His6x	 M.	musculus	 pFL	
TBL1XR1	 134-514	 N-His6x	 M.	musculus	 pFL	
TBL1XR1	 163-514	 N-His6x	 M.	musculus	 pFL	






the	 cDNA.	PCR	 cycling	was	 carried	out	using	PfuUltra	 II	HS	DNA	polymerase	 from	Agilent	
Technologies	 following	 a	 manufacturer-specified	 PCR	 protocol.	 The	 PCR	 reaction	 buffer	
















In	 general,	 approximately	 1	 µg	 of	 DNA	 was	 added	 to	 a	 solution	 containing	 10	 units	 of	
appropriate	restriction	enzymes	(all	from	New	England	Biolabs,	NEB)	to	a	total	volume	of	20	

































































Protein	 Construct	 Tag	 Organism	 Vector	
TBL1X	 1-527	 N-His6x	 M.	musculus	 pEC-KHC	
TBL1X	 127-527	 N-His6x	 M.	musculus	 pEC-KHC	
TBL1X	 139-527	 N-His6x	 M.	musculus	 pEC-KHC	
TBL1X	 150-527	 N-His6x	 M.	musculus	 pEC-KHC	




TBL1X	 171-527	 N-His6x	 M.	musculus	 pEC-KHC	
TBL1X	 176-527	 N-His6x	 M.	musculus	 pEC-KHC	
















buffer.	 250	 ng	 of	 linearised	 vector	was	 loaded	 into	 each	well	 in	 a	 0.8%	 agarose	 gel.	 The	
linearised	vector	bands	were	cut	out	form	the	gel	and	purified	using	a	QIAquick	Gel	Extraction	






















melting	 temperatures	 rather	 than	 matching	 the	 primer	 lengths	 as	 suggested	 by	 the	
manufacturer.	
Table	2.4.1.	Constructs	made	using	Gibson	Assembly	
Protein	 Construct	 Tag	 Organism	 Vector	
TBL1XR1	 1-514	 C-His6x	 M.	musculus	 pEC-MCN-CS	
TBL1XR1	 127-514	 C-His6x	 M.	musculus	 pEC-MCN-CS		
TBL1XR1	 159-514	 C-His6x	 M.	musculus	 pEC-MCN-CS		
TBL1XR1	 163-514	 C-His6x	 M.	musculus	 pEC-MCN-CS		
TBL1XR1	 1-514	 No	tag	 M.	musculus	 pEC-MCN-CS	
TBL1XR1	 1-514	 N-His6x	 M.	musculus	 pEC-MCN-CS	
HDAC3	 1-428	 No	tag	 H.	sapiens	 pEC-MCN-CS	





Table	 2.5.1	 contains	 a	 list	 of	 constructs	 made	 using	 site-directed	 mutagenesis.	
Complementary	primer	pairs	(forward	and	reverse)	with	the	desired	mutation(s)	were	used	





Protein	 Construct	 Tag	 Organism	 Vector	
TBL1XR1	 134-514	E171A	 N-His6x	 M.	musculus	 pFL	
TBL1XR1	 134-514	E171Q	 N-His6x	 M.	musculus	 pFL	
TBL1XR1	 134-514	C214S	 N-His6x	 M.	musculus	 pFL	
TBL1XR1	 134-514	D313N	 N-His6x	 M.	musculus	 pFL	
TBL1XR1	 134-514	E351A	 N-His6x	 M.	musculus	 pFL	
TBL1XR1	 134-514	E351D	 N-His6x	 M.	musculus	 pFL	
TBL1XR1	 134-514	D369A	 N-His6x	 M.	musculus	 pFL	





















On	 day	 two,	 a	 single	 EMBacY	 colony	 was	 inoculated	 into	 5ml	 of	 LB	 with	 appropriate	
antibiotics.	The	cells	were	grown	overnight	at	37˚C	with	shaking	for	16-20	h.	
On	day	three,	the	overnight	culture	was	diluted	in	a	ratio	of	1:200	into	250	ml	of	pre-warmed	





























discarded	and	the	cells	were	 resuspended	 in	 the	 remaining	250	µl	of	SOC.	The	cells	were	
plated	onto	EMBacY	plates	that	contained	X-gal	and	IPTG	(see	section	2.6.1).	
After	24-48	hours	the	plates	were	inspected.	Between	5	and	10	white	colonies,	which	were	
the	 result	of	 recombination	of	 the	 transfer	plasmid	 into	 the	middle	of	 the	LacZ	gene	and	















solution	 was	 centrifuged	 for	 5	 minutes	 at	 10,000	 g	 at	 4˚C,	 washed	 with	 ethanol,	 and	
centrifuged	again.		


























































resuspended	 in	 50	 µl	 of	 2X	 sample	 buffer	 (2XSB,	 Tris	 HCl	 pH	 6.8	 100	 mM,	 10%	 ß-
mercaptoethanol,	4%	SDS,	0.2%	bromophenol	blue,	20%	glycerol).	The	cells	were	 induced	
with	1	mM	IPTG	and	temperature	set	to	18˚C.	The	cells	were	grown	overnight.	In	the	morning	


























lengths	 were	 varied	 to	 determine	 whether	 different	 growth	 conditions	 would	 support	
(improved)	protein	expression.	
2.8.2 Heterologous	expression	in	Insect	cells	





L-glutamine,	 90	 ml/L	 of	 medium	 of	 200	 mM	 L-glutamine	 was	 added.	 The	 cells	 were	
resuspended	in	appropriate	lysis	buffer	(Table	2.8.1)	and	sonicated	on	ice	at	10	µm	amplitude	


























































virus:medium,	 depending	on	 the	 strength	of	 the	 virus	 stock.	 Antibiotic-antimycotic	 (100X	






Insect	 cell	 pellets	were	 resuspended	 to	 a	 final	 concentration	 of	 20%	 (w/v)	 in	 lysis	 buffer	
containing	20	mM	Tris	HCl	pH	7.5,	500	mM	NaCl,	10	mM	imidazole,	one	complete	EDTA	free	















concentrated	using	VivaSpin	R15	30	 kDa	MWCO	concentrators	 (Sartorius)	 to	 a	 volume	of	
approximately	 2.5	ml.	 This	 sample	was	 subjected	 to	 size-exclusion	 chromatography	using	




2.11 		Co-crystallisation	 of	 TBL1X/TBL1XR1	 with	 MeCP2	 NID	
peptide	
2.11.1 	Crystallisation	screening	




between	 4	 and	 20	 mg/ml.	 The	 crystallisation	 screens	 used	 were	 MAGIC	 I	 and	 MAGIC	 II	
(Crystallisation	Facility,	MPI	Martinsried),	 Index	HT	(Hampton	Research),	JCSG+	(Molecular	
Dimensions),	 COMPLEX	 I	 and	 COMPLEX	 II	 (Crystallisation	 Facility,	 MPI	 for	 Biochemistry,	
Martinsried),	 Anions	 suite	 (Qiagen	NeXtal),	 and	AmSO4	 suite	 (Qiagen	NeXtal).	 The	 plates	










a	 few	 screens	 also	 examined	 the	 effect	 of	 pH	 on	 crystallisation.	 Different	 protein	




















sequence	 alignment	 file	 (*.aln)	 using	 the	 human	 TBL1XR1	 and	mouse	 TBL1XR1	 was	 also	









on	 the	 calculated	 Matthew’s	 coefficients	 (VM)	 for	 different	 number	 of	 molecules	 in	 the	
asymmetric	 unit	 (Equation	 2.1	 and	 2.2),	 the	 most	 likely	 asymmetric	 unit	 contained	 4	
molecules	with	a	solvent	content	of	44%	(Table	2.11.1),	as	the	mode	of	Matthew’s	coefficient	
is	2.34	Å/Da	 (Kantardjieff	 and	Rupp,	2003).	 This	was	also	used	as	an	 input	parameter	 for	
PHASER.	








































All	 thermal	denaturation	assays	were	done	 in	 triplicate	 in	 clear	96-well	 iQ	Real-Time	PCR	





finding	an	appropriate	 concentration	of	protein	 to	use,	different	 additives	 and/or	buffers	







at	 25˚C	using	 a	BIAcore	 T200	 (GE	 Life	 Sciences)	 and	an	 SA	 chip	 (Series	 S	 Sensor	Chip,	GE	
Healthcare).	
All	4	channels	were	first	washed	with	buffer	(20	mM	Tris	HCl	pH	7.5,	200	mM	NaCl,	1	mM	
DTT).	Next	20	nM	solutions	of	MeCP2	peptides	were	 injected	onto	 the	 chip	 to	maximum	
Response	Unit	(RU)	values	of	about	10	(𝑅-;<$(=).	This	ensured	that	the	maximum	RU	values	





was	 left	 as	 reference,	 while	 channel	 2,	 3,	 and	 4	 had	 wild-type	 MeCP2285-313,	 wild-type	
MeCP2285-309,	and	MeCP285-313	R306C	peptides	immobilized	on	them,	respectively.		
	
















Electrophoretic	 mobility	 shift	 assays	 (EMSAs)	 were	 used	 to	 determine	 whether	 MeCP2	
minigene	 protein	 had	 a	 functional	MBD	 and	 could	 discriminate	 between	methylated	 and	
non-methylated	DNA.	They	were	also	used	to	test	whether	binding	of	DNA	to	MeCP2	MBD	




(Biomers	 GmbH)	 (Table	 2.14.1)	 were	 resuspended	 in	 nuclease-free	 water	 to	 a	 final	
concentration	of	1	mM.	25	µl	of	labelled	and	30	µl	of	unlabelled	(1:1.2	molar	ratio)	DNA	was	






Table	 2.14.1.	 Fluorescently-labelled	methylated	 DNA	 used	 in	 EMSAs.	 The	 top	 strand	 had	 the	 5’	
modification	 with	 DY-681	 fluorophore,	 while	 the	 bottom	 stand	 was	 unlabeled.	 The	 ‘5’	 in	 the	
sequence	stands	for	5-methylcytosine.		
Top	strand	(5’	DY-681)	 5’ ata gaa gaa ttc 5gt tcc ag  3’ 

































washed	 3x	 (no	 incubation)	 with	 300	 µl	 of	 200	 mM	 ammonium	 bicarbonate	 in	 50%	
acetonitrile.	





were	 sonicated	 for	 5	 minutes	 in	 a	 waterbath.	 Data	 were	 collected	 using	 a	 Brüker	












samples	 were	 supplemented	 with	 0.005%	 Tween	 20	 (Thermo	 Fisher).	 Datapoints	 were	
analysed	using	non-linear	regression	with	eq.	2.2	where	Rf	and	Rb	are	the	anisotropies	of	the	
free	 and	bound	 receptor,	 respectively.	 	 LT	 is	 the	 total	 ligand	 concentration,	 and	KD	 is	 the	
dissociation	 constant.	 Anisotropy	 is	 plotted	 as	 the	 Y	 value	 and	 X	 value	 plotted	 is	 protein	
concentration.	















2.18 		Pulldown	 assays	 of	 recombinant	 purified	 TBL1X	 with	
MeCP2	
Pulldown	 assays	 were	 carried	 out	 using	 purified	 mouse	 TBL1X176-527	 and	 chemically	
synthesised	 N-biotinylated	 MeCP2285-313	 peptides	 containing	 K304E,	 K305R,	 K306C,	 and	





























Previously,	 unpublished	 experiments	 done	 by	 Dr.	Matthew	 Lyst	 and	 his	 summer	 student	
Žygimantė	 Tarnauskaitė	 in	 Prof.	 Adrian	 Bird’s	 lab	 in	 Edinburgh	 showed	 that	 the	minimal	
















LisH	domain,	which	 is	 the	tetramerisation	domain,	but	kept	 the	C-terminal	WD40	domain	
intact.	 The	 bacterial	 expression	 constructs	 were	 based	 on	 multiple	 secondary	 structure	
prediction	 softwares	 and	 care	was	 taken	not	 to	 disrupt	 any	of	 these	predicted	 structural	
elements	 as	 that	 could	 lead	 to	 insoluble	 protein.	 Furthermore,	 one	 of	 the	 constructs,	
TBL1X176-527,	was	chosen	for	codon	optimisation	(synthesized	by	MWG)	to	determine	whether	







Protein	 Construct	 Tag	 Organism	 Vector	
TBL1X	 1-527	 N-His6x	 M.	musculus	 pEC-KHC	
TBL1X	 127-527	 N-His6x	 M.	musculus	 pEC-KHC	
TBL1X	 139-527	 N-His6x	 M.	musculus	 pEC-KHC	
TBL1X	 141-527	 N-GST	 H.	sapiens	 pEC-KGC	
TBL1X	 150-527	 N-His6x	 M.	musculus	 pEC-KHC	
TBL1X	 159-527	 N-GST	 H.	sapiens	 	 pEC-KGC	
TBL1X	 162-527	 N-His6x	 M.	musculus	 pEC-KHC	
TBL1X	 171-527	 N-His6x	 M.	musculus	 pEC-KHC	
TBL1X	 176-527	 N-His6x	 M.	musculus	 pEC-KHC	
TBL1X	 176-527	Codon	optimised	 N-His6x	 M.	musculus	 pEC-KHC	
TBL1XR1	 1-514	 C-His6x	 M.	musculus	 pEC-MCN-CS	
TBL1XR1	 127-514	 C-His6x	 M.	musculus	 pEC-MCN-CS		
TBL1XR1	 159-514	 C-His6x	 M.	musculus	 pEC-MCN-CS		
TBL1XR1	 163-514	 C-His6x	 M.	musculus	 pEC-MCN-CS		
3.3 Expression	tests	of	TBL1X/TBL1XR1	in	Escherichia	coli	
Initially	expression	 tests	 for	TBL1X	and	TBL1XR1	were	done	 in	Escherichia	 coli	BL-21(DE3)	
cells.	 Pulldowns	 done	 by	 Dr.	 Uma	 Jayachandran	 on	 the	 two	 human	 TBL1X	 constructs	
(hTBL1141-527	 and	hTBL1159-527)	 showed	 that	 these	 two	 constructs	 expressed	 the	protein	of	
interest,	 though	 at	 low	 levels.	 It	 was	 decided	 to	 try	 to	 purify	 TBL1X141-527	 construct	 and	
establish	a	purification	protocol,	after	which	expression	optimization	could	be	undertaken.	
However,	after	multiple	attempts	of	purification,	TBL1X141-527	always	aggregated,	as	observed	
by	 size	 exclusion	 chromatography.	 Because	 of	 the	 low	 expression	 levels	 and	 aggregation	
problems	with	the	TBL1X141-527	construct,	as	well	as	the	desire	to	perform	biophysical	assays	
on	the	mouse	TBL1X/TBL1XR1	due	to	the	availability	of	various	mouse	MeCP2	peptides	in	the	
Bird	 lab,	 these	 two	 human	 constructs	 were	 put	 aside.	 Instead,	 the	 expression	 levels	 of	
multiple	mouse	TBL1X	constructs	were	 tested.	Two	of	 them,	TBL1X162-527	 and	TBL1X176-527,	
showed	expression	of	 the	protein	of	 interest,	although	the	expression	 levels	of	 these	two	
constructs	did	not	exceed	that	of	TBL1X141-527	and	TBL1X159-527	(Figure	3.3.1).	At	the	same	time,	















expression	 that	was	not	 sufficient	 for	 further	 characterisation.	Both	162-527	and	176-527	TBL1X	
constructs	 expressed	 at	 quantities	 sufficient	 to	 warrant	 purification	 attempts.	 hTBL1X	 refers	 to	
human	version	of	the	protein.		
Protein	 Construct	 Expresses	 Soluble	protein	
TBL1X	 1-527	 No	 	
TBL1X	 127-527	 No	 	
TBL1X	 139-527	 No	 	
hTBL1X	 141-527	 Yes	 Yes	
TBL1X	 150-527	 No	 	
hTBL1X	 159-527	 Yes	 Yes	
TBL1X	 162-527	 Yes	 Yes	
TBL1X	 171-527	 No	 	
TBL1X	 176-527	 Yes	 Yes	
TBL1X	 176-527	Codon	optimised	 No	 	
TBL1XR1	 1-514	 No	 	
TBL1XR1	 127-514	 No	 	
TBL1XR1	 159-514	 No	 	








is	 a	 methionine	 auxotroph,	 which	 can	 be	 used	 to	 label	 proteins	 with	 selenomethionine.	
BL21(DE3)	pRIPL	strain	carries	a	plasmid	encoding	extra	copies	 for	the	tRNAs	that	are	the	











Protein	 Construct	 Strain	(E.	coli)	 Soluble	protein	
TBL1X	 162-527	 RIPL	 No	
TBL1X	 176-527	 RIPL	 No	
TBL1XR1	 1-514	 RIPL	 No	
TBL1X	 162-527	 T7	Express	 No	
TBL1X	 176-527	 T7	Express	 No	
TBL1XR1	 1-514	 T7	Express	 Yes	
TBL1X	 176-527	 B834	 No	
TBL1XR1	 1-514	 B834	 Yes	
	
TBL1X176-527	was	taken	further	for	purification	trials	for	two	interconnected	reasons.	First,	as	
mentioned	previously,	 it	was	the	minimal	 fragment	that	had	been	shown	to	 interact	with	
MeCP2.	As	the	end	goal	was	the	crystallization	of	the	WD40	domain	of	this	protein,	any	extra	
amino	acids	could	prove	detrimental	for	crystal	growth	as	they	could	be	mobile	and	interfere	






The	 cells	were	 lysed	 under	 pressure	 and	 the	 resulting	 lysate	 spun	 down	 to	 separate	 the	
insoluble	proteins	and	other	cellular	debris.	The	soluble	fraction	was	separated	over	an	IMAC	
(Immobilised	metal-affinity	chromatography)	column	charged	with	Ni2+	ions	to	allow	the	His-










On	 SDS-PAGE,	 there	 is	 no	 obvious	 over-expression	 of	 the	 recombinant	 protein	 when	
uninduced	 and	 induced	 samples	 are	 compared	 (Figure	 3.4.2,	 leftmost	 black	 arrow).	 The	
protein	also	does	not	seem	to	form	inclusion	bodies	during	expression	as	evident	by	the	lack	
of	a	major	protein	band	at	around	38	kDa	in	the	insoluble	fraction.	The	major	band	seen	in	













Fractions	 containing	 TBL1X176-527	 (1A9	 to	 1B2,	 Figure	 3.4.2)	 were	 pooled	 and	 dialysed	














elution	 fractions	 (Figure	 3.4.3,	 rightmost	 black	 arrow),	 although	 that	 did	 not	 constitute	 a	
majority	of	the	protein.	 
	















of	 untagged	 proteins	 due	 to	 the	 presence	 of	 histidine	 runs	 in	 native	 proteins.	 Since	 the	
TBL1X176-527	 construct	 does	 not	 contain	 polyhistidine	 runs	 in	 its	 sequence,	 and	 the	
hexahistidine	 tag	 had	 been	 cleaved	 off,	 it	was	 theorised	 that	 the	 contaminating	 proteins	
















The	 appropriate	 fractions	 were	 again	 pooled	 and	 separated	 by	 size-exclusion	
chromatography.	This	was	performed	to	analyse	the	heterogeneity	of	the	sample,	as	well	as	


























with	 two	different	 concentrations	 of	 IPTG	 at	 different	 temperatures	were	 tested.	 Terrific	
Broth	 sometimes	 shows	 better	 protein	 expression	 levels	 as	 it	 contains	 both	 K2HPO4	 and	
KH2PO4	as	a	buffering	agent,	which	reduces	media	acidification	that	is	detrimental	to	E.	coli	
growth.	 The	 tests	were	 done	 first	 in	 BL21(DE3)	 cells	with	 300	µM	 IPTG	 (Table	 3.5.1)	 and	
grown	overnight.	Pulldowns	were	done	on	overnight	samples,	although	for	each	condition	






100	µM	IPTG	 20˚C	 25˚C	 30˚C	 37˚C	
2XTY	 Yes	 N/A	 Yes	 No	
Terrific	Broth	 Yes	 N/A	 Yes	 No	
300	µM	IPTG	 20˚C	 25˚C	 30˚C	 37˚C	
2XTY	 Yes	 Yes	 Yes	 No	
Terrific	Broth	 Yes	 Yes	 Yes	 No	
	
When	the	cells	were	grown	at	37˚C	there	was	no	TBL1X176-527	present	in	the	pulldowns.	For	
















weight	 again	 present	 in	 both	 20˚C	 and	 30˚C	 samples,	 however,	 similarly,	 their	 levels	 of	
expression	were	not	greater	than	those	at	18˚C.	For	both	100	µM	and	300	µM	IPTG	tests	the	
6-hour	 time	point	did	not	 reveal	 any	 increase	 in	 the	 recombinant	protein	 levels	 in	 either	













tested,	 the	 codon-optimised	 construct	 had	 abolished	 the	 expression	 of	 the	 protein	
completely.		







increase	 the	 yields	 were	 unsuccessful.	 Attention	 was	 turned	 towards	 insect	 cells	 and	
baculovirus	 expression	 system	 as	 the	 human	 TBL1XR1	 WD40	 domain	 that	 had	 been	
crystallised	(PDB	ID:	4LG9)	was	expressed	in	Spodoptera	frugiperda	Sf9	cell	line.		
Six	constructs	were	cloned	into	 insect	cell	expression	vectors;	three	 in	TBL1X	and	three	 in	
TBL1XR1	 that	 started	 from	equivalent	 amino	 acid	 positions	 (Table	 3.6.1).	 TBL1X176-527	 and	
TBL1XR1163-514,	 which	 were	 constructs	 starting	 at	 equivalent	 amino	 acids	 in	 these	 two	

























TBL1X	 1-527	 59.0	 N-His6x	 M.	musculus	 pFL	
TBL1X	 148-527	 43.7	 N-His6x	 M.	musculus	 pFL	
TBL1X	 176-527	 40.7	 N-His6x	 M.	musculus	 pFL	
TBL1XR1	 1-514	 58.0	 N-His6x	 M.	musculus	 pFL	
TBL1XR1	 134-514	 43.9	 N-His6x	 M.	musculus	 pFL	





tendency	 of	 these	 cells	 to	 clump	 together	 which	 often	 results	 in	 cell	 death.	 This	 can	 be	







E.	coli.	These	experiments	were	 repeated	multiple	 times	and	each	 time	 the	expression	of	
protein	in	Hi5	cells	was	highly	variable	while	it	was	consistent	in	Sf9	cells.	To	confirm	that	the	
proteins	 seen	 in	 the	 pulldowns	 were	 indeed	 various	 constructs	 of	 TBL1X	 and	 TBL1XR1,	
Western	blots	were	carried	out	using	an	antibody	against	the	C-terminus	of	TBL1XR1,	which	
is	 able	 to	 recognise	 both	 TBL1X	 and	 TBL1XR1.	 As	 can	 be	 seen	 from	 Figure	 3.6.2,	 the	














M	 -	Medium,	W	 -	wash,	 E1-E4	 -	 Elution	 1-4.	 Due	 to	 a	 loading	 error,	 there	was	 no	 pulldown	 for	
TBL1X176-527,	but	purification	trials	at	a	later	date	showed	that	the	protein	expressed	to	high	levels	







Figure	 3.6.2.	Western	blots	 of	 pulldown	 fractions	 seen	 in	 Figure	 3.6.1	using	 an	 antibody	 against	
TBL1XR1	C-terminus	which	is	also	able	to	recognize	TBL1X.	TBL1X148-527	appears	twice,	again	due	to	













medium	 ratio	 was	 between	 1:20	 and	 1:50	 depending	 on	 the	 virus	 stock	 used,	 although	
generally	the	V2	stocks	were	high	enough	in	titre	to	be	used	at	1:50	dilution.	Using	more	virus	
than	1:20	(e.g.	1:10)	resulted	in	very	quick	growth	arrest	and	cell	death	due	to	high	rate	of	




















to	 remove	any	unbound	protein,	 and	bound	protein	eluted	with	a	 gradient	of	0-250	mM	










with	 black	 arrow)	 bound	 to	 the	 column	 and	 eluted	 separately	 (fractions	 18-22)	 from	 most	
contaminants	(fractions	12-16).		
There	were	some	contaminants	present	so	in	order	to	separate	TBL1X	from	these,	a	cation	
exchange	 column	was	 used.	 Previously	 an	 anion	 exchange	 column	 had	 been	 used	 in	 the	
purification	attempts	with	the	E.	coli	protein	as,	according	to	ProtParam,	the	predicted	pI	of	
the	protein	was	5.96	and	would	thus	would	carry	an	overall	negative	charge	 in	the	buffer	
used	 (pH	7.5).	However,	 that	step	resulted	 in	only	a	partial	 recovery	of	protein,	 so	 it	was	
investigated	whether	it	was	possible	to	clean	up	the	protein	with	a	cation-exchange	column	
instead	by	allowing	the	contaminants	to	bind	and	collecting	the	protein	of	interest	from	the	













































resulted	 in	 considerable	 precipitation	 developing	 in	 the	 dialysis	 bag.	However,	 as	 before,	











one	 around	 45	ml	 corresponded	 to	 the	 void	 volume	 and	 consists	 of	 larger	 proteins	 and	
aggregates.	 The	 second	 monodisperse	 peak	 around	 55	 ml	 contained	 mostly	 TBL1X148-527	
(fractions	 C4-C6).	 As	 can	 be	 seen	 from	 the	 A260/A280	 ratio,	 there	 was	 virtually	 no	






from	 2	 ml	 to	 1	 ml,	 resulting	 in	 better	 separation	 of	 some	 of	 the	 earlier	 contaminants		








protocol	 was	 tested	 using	 TBL1XR1134-514	 and	 TBL1XR1163-514	 as	 well	 as	 on	 TBL1X176-527	
construct	and	all	yielded	similar	amounts	of	protein	with	comparable	purity.		
3.9 Characterising	 TBL1X/TBL1XR1	 WD40	 domain	 stability	
through	thermal	denaturation	assay	
To	 assess	 the	 stability	 of	 the	 purified	 protein	 and	 determine	 the	 effect	 of	 additives	 and	
different	buffers,	a	number	of	thermal	denaturation	assays	were	performed.	This	assay	tracks	

































Figure	 3.9.2.	 Stability	 of	 TBL1X148-527	 in	 different	buffers.	Melting	 temperature	of	 Tris-HCl	 pH	7.5	
sample	(60.7±0.24°C)	was	set	as	the	reference.	The	error	bars	are	one	standard	deviation.	
Another	screen	assessed	the	effects	of	different	salts	on	the	stability	of	TBL1XR1134-514	(Figure	
3.9.3).	 Increasing	 concentrations	 of	 Na+,	 NH4+,	 and	 SO42-	 ions	 increased	 the	 melting	
temperature	 of	 TBL1XR1134-514.	 However,	 while	 lowering	 NaCl	 concentration	 slightly	
destabilised	the	protein	and	increasing	NaCl	stabilised	it,	the	effect	was	minimal.	Increasing	
ammonium	 sulphate	 concentration	 from	 100	 mM	 to	 400	 mM	 changed	 the	 melting	
temperature	of	the	protein	from	+1.67˚C	to	+5.67±0.4°C	when	compared	to	the	reference	









































shown	 that	 the	 protein	 was	 relatively	 stable	 between	 pH	 6.0	 and	 10.0,	 with	 a	 melting	
temperature	 around	 61-63˚C.	While	 higher	 pH	 values	were	 not	 probed,	 lowering	 the	 pH	
below	6.0	resulted	 in	a	dramatic	decrease	 in	the	melting	temperature	of	the	protein,	and	
lowering	 the	 pH	 to	 5.5	 or	 lower	 resulted	 in	 protein	 aggregation,	 at	 least	 in	 the	 buffer	
conditions	tested.	The	effects	of	different	salts	at	different	concentrations	were	also	probed.	
It	was	shown	that	while	Na+,	Cl-,	NH4+	and	SO42-	were	stabilising	at	increasing	concentrations,	














that	 RTT	 mutations	 abolish	 this	 interaction,	 although	 the	 structural	 basis	 for	 this	 was	
unknown.	To	increase	the	probability	of	getting	a	co-crystallised	TBL1XR1-MeCP2	complex,	











electrostatic	 interactions.	 The	 effects	 of	 RTT	 mutations	 on	 the	 interaction	 between	
TBL1X/TBL1XR1	 and	MeCP2	were	 also	 investigated	 using	 in	 vitro	 pulldowns	 and	 thermal	
denaturation	 assays	 with	 purified	 recombinant	 proteins.	 Finally,	 the	 affinity	 of	 this	








while	 electropositive	 areas	 are	 coloured	 in	 blue.	 The	 area	 containing	 the	 E364	 residue	 that	was	
found	 to	 be	 critical	 for	 mediating	 interaction	 with	 MeCP2	 has	 been	 circled.	 This	 area	 had	 a	
pronounced	electronegative	character.	
4.2 MeCP2	 interacts	 with	 TBL1XR1	 in	 a	 salt-dependant	
manner	in	vitro	
The	effect	of	 increasing	concentrations	of	NaCl	and	(NH4)2SO4	on	the	 interaction	between	
MeCP2285-309	 and	 TBL1XR1134-514	 (Referred	 to	 as	 both	 TBL1XR1	 and	 TBL1XR1134-514	 in	 this	
chapter)	was	probed	using	 thermal	denaturation	assay.	As	 the	protein	purification	buffer	
contained	200	mM	NaCl,	it	was	necessary	to	establish	whether	MeCP2	bound	to	TBL1XR1	in	
these	 conditions,	 or	 whether	 the	 buffer	 conditions	 needed	 to	 be	 changed.	 The	 effect	 of	
(NH4)2SO4	 was	 also	 probed,	 as	 ammonium	 sulphate	 is	 a	 common	 precipitation	 agent	 in	
protein	crystallisation.	The	effect	of	the	salt	on	the	protein	alone,	as	well	as	on	the	protein	
and	peptide	interaction	was	analysed.	If	the	conditions	tested	favoured	binding	of	the	wild	
type	MeCP2	peptide	 to	TBL1XR1,	 an	 increase	 in	 the	melting	 temperature	would	 likely	be	




















a	 3˚C	 increase	 in	 the	 thermal	 stability	 of	 TBL1XR1	 was	 observed	 upon	 peptide	 addition,	
although	 the	magnitude	of	 this	 change	was	 smaller	 than	what	was	observed	with	 similar	
concentrations	of	NaCl.	However,	when	200	mM	(NH4)2SO4	was	added	there	was	very	little	
difference	 between	 the	 melting	 temperatures	 of	 the	 protein	 alone	 and	 the	 protein	 and	













4.3 Rett	 mutations	 in	 MeCP2	 abolish	 the	 interaction	 with	
TBL1X	and	TBL1XR1	












tested	 RTT	mutants	 (K304E,	 K305R,	 and	R306C)	 show	 any	 binding	 to	 TBL1X.	MeCP2285-313	
containing	 a	 phosphorylated	 T308	 is	 not	 able	 to	 pull	 down	 TBL1X	 either,	 consistent	with	











TBL1X/TBL1XR1	 and	 MeCP2.	 This	 could	 help	 treat	 either	 MeCP2	 overexpression	 or	 RTT	
syndrome.	I	used	TBL1X148-527	purified	from	insect	cells	for	the	thermal	denaturation	assay.	If	
wild-type	MeCP2	NID	peptide	bound	to	TBL1X,	but	R306C	mutant	did	not,	I	would	observe	a	


















bind	 to	 wild-type	 MeCP2	 peptide	 using	 analytical	 gel	 filtration	 (Figure	 4.3.3).	 As	 it	 was	
impossible	to	observe	the	peptide	through	absorbance	at	280	nm	as	 it	 lacks	any	aromatic	































































light	will	 be	 depolarised.	 This	will	 result	 in	 low	anisotropy.	However	when	 the	peptide	 is	
bound	 to	 a	much	 larger	 protein,	 the	 tumbling	 rate	will	 be	much	 lower	 and	 the	 resulting	
anisotropy	will	be	higher	(Figure	4.4.1).	
	
Figure	 4.4.1.	 Principle	 of	 fluorescence	 anisotropy	 assay.	 Depolarised	 light	 passes	 through	 a	







(F⊥)	 light	 (low	anisotropy).	However,	 if	 the	 fluorescently-tagged	 small	molecule	 is	 attached	 to	a	
larger	molecule,	 the	 tumbling	 rate	will	 decrease	 and	 the	 emitted	 light	 is	 largely	 polarised	 (high	
anisotropy).		
Depending	on	 the	 software	used,	 the	 reported	values	 from	the	experiment	can	either	be	






















Peptide	concentration	(nM)	 Intensity	 Average	anisotropy	 StDev	of	anisotropy	
400	 Saturated	 N/A	 N/A	
200	 332	 0.062	 0.004	
100	 119	 0.074	 0.002	
50	 49	 0.083	 0.002	
25	 20	 0.088	 0.002	
12.5	 8	 0.081	 0.004	






Concentration	(nM)	 Intensity	 Average	anisotropy	 StDev	of	anisotropy	
400	 512	 0.049	 0.001	
200	 196	 0.059	 0.001	
100	 82	 0.069	 0.003	
50	 38	 0.078	 0.002	
25	 17	 0.082	 0.005	
12.5	 8	 0.077	 0.005	
6.25	 4	 0.075	 0.003	
	
For	 MeCP2289-309	 and	 MeCP2298-309	 concentrations	 between	 25-300	 nM	 and	 50-400	 nM,	
respectively,	produced	sufficient	signal.	 In	MeCP2	and	TBL1XR1	binding	experiments,	both	
50	 and	 100	 nM	 of	 MeCP2289-309	 and	 MeCP2298-309	 were	 tested	 again	 on	 the	 day	 of	 the	
experiment,	 as	 the	 maximum	 intensity	 values	 varied	 between	 experiments.	 	 Whichever	
concentration	produced	 the	 lowest	amount	of	 signal	above	 the	 threshold	of	20	was	 then	























the	anisotropy.	While	 it	was	possible	 to	analyse	 the	data	using	non-linear	 regression	and	
calculate	a	KD	from	the	data	(Table	4.4.3),	this	value	is	likely	to	be	erroneous	as	the	anisotropy	
plateaued	 at	 low	 concentrations	 of	 TBL1XR1.	 This	would	 skew	 the	 calculated	 KD	 towards	
lower	values.	
	








Figure	 4.4.3.	 Fluorescence	 anisotropy	 assay	 measuring	 the	 binding	 of	 MeCP2298-309	 peptide	 to	
TBL1XR1134-514.	 Concentration	 of	 MeCP2	 peptide	 was	 100	 nM.	 BSA	 was	 included	 as	 a	 negative	









change	 depending	 on	 how	 long	 the	 solution	 has	 been	 left	 to	 reach	 equilibrium,	 I	 set	 up	

































in	 the	 free	 electron	 cloud	 of	 the	 gold	 atoms,	 giving	 rise	 to	 surface	 plasmons,	 which	 are	
electromagnetic	waves.	This	absorption	of	photons	and	resulting	drop	in	reflectance	can	be	
detected	 in	 the	 reflected	 light	beam	hitting	a	detector	 (Figure	4.4.5A).	As	 ligands	bind	 to	






















solved	 the	 non-specific	 binding	 issue.	 It	 introduced	 a	 problem	with	 buffer	mismatch	 and	
subsequent	large	injection	start	and	stop	peaks,	but	as	the	kinetics	of	the	interaction	were	
too	fast	to	be	resolved	anyway,	affinities	could	only	be	calculated	from	steady-state.		
Figure	 4.4.6	 shows	 the	 binding	 curves	 of	 the	 three	 peptides	 to	 TBL1XR1134-514.	 The	
dimensionless	 response	 units	 (RU)	 correspond	 to	 change	 of	 mass	 on	 the	 chip	 surface.	




310-313	 may	 be	 involved	 in	 enhancing	 this	 interaction.	 These	 were	 consistent	 with	 the	










































































To	 obtain	 co-crystals	 of	MeCP2	 and	 TBL1XR1,	 two	 different	 approaches	 could	 have	 been	
taken.	MeCP2	and	TBL1XR1	could	have	been	co-crystallised	by	either	co-purifying	or	mixing	
the	 two	 proteins	 together	 to	 form	 a	 complex,	 followed	 by	 crystallisation.	 Alternatively,	
MeCP2	 could	 have	 been	 soaked	 into	 crystals	 of	 TBL1XR1.	 Analysing	 the	 human	 TBL1XR1	
crystal	structure	and	conditions	showed	that	the	conditions	included	high	salt	(2	M	AmSO4),	
which	would	have	abolished	the	binding	of	MeCP2	to	TBL1XR1	as	revealed	by	previous	TDA	
experiments.	 Furthermore,	 the	 observed	 crystal	 packing	 would	 have	 been	 unable	 to	
accommodate	 the	 MeCP2	 peptide,	 as	 the	 central	 channel	 of	 the	 WD40	 domain	 makes	
contacts	with	a	 loop	from	a	TBL1XR1	molecule	 in	an	adjacent	asymmetric	unit,	effectively	












Understanding	 the	 interaction	between	TBL1XR1	and	MeCP2	 in	 atomic	detail	 should	 give	
insight	into	how	mutations	in	the	NID	lead	to	RTT.	By	understanding	the	binding	site	in	detail,	
as	well	as	which	residues	are	critical	for	this	interaction	to	occur,	it	may	be	possible	to	use	
rational	 design	 for	 the	 development	 of	 small	 drug-like	 molecules.	 This	 could	 lead	 to	
























as	 often	 the	 wells	 had	 gelatinous	 precipitation	 or	 spherulites,	 which	 indicated	 that	 the	











✝denotes	 overnight	 light	 amorphous	 precipitation.	 Empty	 cells	 indicate	 clear	 drops.	 *	 denotes	
microneedles	that	grew	after	five	days.	
	 PEG	400	 PEG	550	 PEG	2000	 PEG	3350	 PEG	5000	
10%	 	 	 	 	 X	
15%	 ✝ ✝	 	 	 X	
20%	 X	 X	 ✝ *	 X	













Table	 5.3.2.	 Hanging	 drop	 results	 for	 co-crystallisation	 of	 TBL1XR1134-514	 (12.6	 mg/ml	 final	
concentration)	mixed	with	MeCP2285-309	 in	1:1.2	protein:peptide	 ratio.	 *	denotes	microneedles,	 °	
denotes	spherulites.	Empty	cells	contained	light	amorphous	precipitation.	
Concentration	 PEG	550	 PEG	1000	 PEG	2000	 Concentration	 PEG	3350	
13%	 	 	 	 21%	 *	
15%	  	 	 23%	 *	
17%	 	 	 ° 	 	


















Table	 5.3.3.	 Hanging	 drop	 results	 for	 co-crystallisation	 of	 TBL1XR1134-514	 (12.6	 mg/ml	 final	
concentration)	mixed	with	MeCP2285-309.	Empty	cells	indicate	light	amorphous	precipitation.	
PEG	3350	 MOPS	pH	6.5	 MOPS	pH	7.0	 MOPS	pH	7.5	 MOPS	pH	8.0	
17%	 	 	 	 	
19%	  	 	 	
21%	 	 	  	
	
A	number	of	plates	were	set	up	in	the	following	weeks.	Because	so	far	the	best	results	had	
been	 obtained	 with	 PEG	 2000	 and	 PEG	 3350,	 the	 plates	 had	 just	 these	 two	 PEGs	 in	





23%	PEG	2000	and	3350	at	 ratios	 ranging	 from	1:10	 to	1:100,	but	no	 crystal	 growth	was	
observed.	Instead	again	the	drops	showed	precipitation.	




spermidine	 to	 crystallisation	 conditions	 containing	 50	 mM	 MOPS	 pH	 7.5	 and	 varying	
concentrations	 of	 PEG	 3350	 (14%-24%,	 2%	 increments)	 produced	 gelatinous	 precipitate,	






were	 very	 similar	 to	 those	 that	 produced	 microneedles,	 with	 the	 exception	 that	 the	
concentration	of	MOPS	buffer	was	100	mM,	not	50	mM,	and	TBL1XR1	concentration	was	
lower	 than	what	was	 initially	 tested.	 These	 conditions	were	 observed	 for	 a	 week	 to	 see	












resolution	 of	 2.5	 Å.	 The	 data	 from	 that	 crystal	 was	 processed,	 after	 which	 molecular	


























































































which	 is	 a	 common	 feature	 of	 WD40	 domains.	 The	 defining	 feature	 of	 WD40	 repeats,	
however,	is	the	DHSW	tetrad,	or	a	variation	of	thereof	(Figure	5.4.4).	This	is	a	conserved	motif	

































density	 was	 present	 for	 the	 sidechains	 of	 residues	 301-306	 in	 the	 MeCP2	 peptide.	 This	



























although	 the	 change	 in	 position	 is	 relatively	 small	 when	 compared	 to	 Y395	 or	 F420.	
Nevertheless,	 the	movement	 of	 E351	might	 represent	 an	 accommodation	 of	 the	MeCP2	
peptide.	 Unfortunately,	 it	 was	 impossible	 to	 compare	 the	 positions	 of	 the	 sidechains	
between	bound	and	unbound	mouse	structures,	as	the	two	unbound	WD40	domains	in	the	








appeared	 to	 be	 the	 major	 binding	 determinants.	 An	 overview	 of	 TBL1XR1	 and	 MeCP2	
residues	involved	in	binding	is	shown	in	Figure	5.4.8.	
	
Figure	 5.4.8.	 A)	 Key	 residues	 involved	 in	MeCP2	 (orange)	 and	 TBL1XR1	 (light	 blue)	 interaction.	



































channel	 and	 contacts	 Y395TBL1XR1,	 F420TBL1XR1,	 and	 Y446TBL1XR1	 (Figure	 5.4.9).	 These	 three	
aromatic	residues	generate	a	hydrophobic	pocket	into	which	P302MeCP2	can	bind.	Y446TBL1XR1	
also	makes	a	hydrogen	bond	with	backbone	carbonyl	of	V300TBL1XR1.	Furthermore,	P302MeCP2	
forms	 a	 hydrogen	 bond	 with	 backbone	 nitrogen	 of	 K305MeCP2.	 	 In	 the	 case	 of	 RTT,	 it	 is	
conceivable	 that	 mutating	 a	 proline	 into	 an	 arginine	 not	 only	 causes	 major	 steric	 and	




unique	φ	 angle	 of	 proline.	 As	 the	 peptide	 binding	 is	 likely	 to	 be	 influenced	 by	 the	 tight	
backbone	conformation	provided	by	 the	proline,	 these	 two	disruptions	would	most	 likely	


























Finally,	 R306MeCP2	 makes	 extensive	 intra-	 and	 intermolecular	 hydrogen	 bonds	 with	 both	
E171TBL1XR1,	but	also	to	the	backbone	carbonyls	of	T299MeCP2	and	L301MeCP2	 (Figure	5.4.12).	
These	intramolecular	hydrogen	bonds	are	likely	to	be	necessary	for	the	peptide	to	maintain	
























and	 Y446F.	 These	 were	 chosen	 based	 on	 the	 structure	 to	 study	 the	 effects	 of	 ionic	
interactions,	hydrogen	bonding,	and	van	der	Waals	interactions.	Because	of	the	number	of	
residues	involved	in	binding,	and	their	potential	mutants,	it	was	not	feasible	to	mutate	them	
all.	Additionally,	C214S	was	made	for	 the	purposes	of	crystallisation,	 in	 the	hopes	that	by	
abolishing	the	formation	of	disulphide	bridges	between	adjacent	molecules	of	TBL1XR1,	 it	
would	 be	 easier	 to	 develop	 a	 protocol	 for	 reproducible	 crystals.	 Both	 the	 site	 directed	
mutagenesis	 and	 subsequent	 protein	 preparations	were	 carried	out	 by	Ceitidh	 Taylor,	 an	
undergraduate	student	under	my	supervision	from	January-April	2016.	The	mutant	proteins	



























WD40	 fold,	melting	 temperatures	of	each	of	 the	mutants	were	measured	using	TDA	 	and	
compared	to	the	wild-type	TBL1XR1	(Figure	5.6.1).	No	mutant	had	a	change	in	the	melting	

















(Figure	 5.6.3	 and	 Figure	 5.6.4),	 although	 previously	 it	 was	 hypothesised	 that	 K305RMeCP2	
might	bind	 to	E351DTBL1XR1	 as	 the	 shorter	 side-chain	of	 the	aspartic	 acid	might	be	able	 to	
accommodate	the	larger	side-chain	of	the	arginine.	
To	 confirm	 that	 the	 protein	 that	was	 co-precipitated	with	wild-type	MeCP2	 peptide	was	











to	 the	 sequence	 of	 another	 invertebrate	 TBL1X,	 a	Drosophila	 melanogaster	 protein	 EBI,	
showed	 the	 two	 proteins	 are	 approximately	 80%	 conserved	 in	 sequence	 in	 the	 WD40	
domains.	 However,	 the	 discrepancies	 were	 interspersed	 in	 sequence.	 As	 the	 peptides	














Figure	 5.6.3.	 Pulldowns	 of	wild-type	 and	mutant	 TBL1XR1134-514	 from	 crude	 cell	 lysates	 using	 N-
biotinylated	MeCP2285-313	R306C.	Black	arrows	indicate	the	location	of	the	expected	TBL1XR1	band.	
	





Figure	 5.6.6	 (raw	 data	 is	 in	 appendix	 10.1).	 All	 of	 the	mutants	 except	 for	 D313N	 gave	 a	

















The	 data	 in	 these	 two	 figures	were	 fit	 to	 Langmuir	 isotherm	using	 non-linear	 regression,	
which	 gave	 the	 KD	 values	 for	 these	mutants	 (Table	 5.6.1).	 E351D	 and	 Y446F	 bound	with	
similar	 affinity	 as	 wild-type	 TBL1XR1.	 As	 expected	 C214S,	 which	 is	 not	 near	 the	 MeCP2	
binding	site,	bound	with	wild-type	affinity	too.	E171A	and	E171Q,	as	well	as	E351A	showed	
much	 weaker	 interactions	 with	 either	 of	 the	 MeCP2	 peptides,	 while	 D313N	 and	 D369A	
produced	responses	that	were	so	 low	that	KD	could	not	be	calculated.	This	 is	because	the	
value	 of	maximum	 response	 unit	 (which	 is	 necessary	 for	 KD	 calculation)	was	 negative,	 or	
because	the	small	change	in	response	upon	binding	produced	KD	values	in	the	range	of	1016	
M.	From	these	data	several	things	can	be	concluded.	First,	as	both	E171A	and	E171Q	showed	
hugely	 diminished	 binding	 to	 MeCP2,	 the	 salt	 bridge	 formed	 between	 E171TBL1XR1	 and	










surface.	 It	 is	 therefore	 possible	 that	 D313N	 grossly	 disturbs	 the	 local	 electrostatic	
environment	 of	 TBL1XR1,	 preventing	 K304MeCP2	 from	 binding.	 Alternatively,	 D313N	might	
help	position	L312	and	N353	so	that	they	are	able	to	contact	MeCP2.	In	the	case	of	D369A,	it	
is	 again	most	 likely	 that	 a	 combination	 of	 loss	 of	 hydrogen	 bonds	 and	 ionic	 interactions	
contributed	to	the	observed	loss	of	binding.	Finally,	mutating	Y446	into	a	phenylalanine	had	
negligible	effect	on	the	KD	values,	indicating	that	the	hydrogen	bond	made	with	the	MeCP2	
backbone	 contributes	 little	 to	 binding,	 and	 that	 the	 aromatic	 side-chain	 that	 contacts	




























The	 mouse	 TBL1XR1	WD40	 domain	 is	 an	 eight-bladed	 beta-propeller	 that	 is	 structurally	
similar	to	the	previously	published	human	TBL1XR1	WD40	domain.	The	MeCP2	NID	peptide	





























also	 a	 frameshift	 mutation	 that	 causes	 the	 protein	 to	 be	 truncated	 at	 amino	 acid	 275.	
Interestingly,	to	date	no	single	nucleotide	variations	have	been	found	in	TBL1X	that	lead	to	
disease.		




















Mutations	 H213Q,	 D328G,	 D370Y,	 and	 H441R	 are	 all	 part	 of	 the	 integral	 DHSW	 tetrads	
described	 earlier,	 and	 it	 is	 likely	 that	 the	 effects	 seen	 are	 due	 to	 both	 disruption	 of	 the	
hydrogen	bonding	in	the	DHSW	tetrad,	as	well	as	changes	in	local	geometry.	Whether	these	
mutations	also	cause	gross	destabilization	of	the	WD40	fold	is	unknown.		
Ex	 vivo	 assays	 performed	 by	 Dr.	Matthew	 Lyst	 have	 shown	 that	 both	 D369E	 and	 P444R	
mutations	abolish	the	binding	of	MeCP2	to	TBLR1	(personal	communication).	P444	is	found	
in	 a	 loop	between	 two	beta	 strands	 near	MeCP2	binding	 site.	 The	P444R	mutation	 likely	
disrupts	both	the	loop	conformation,	as	well	as	MeCP2	binding	through	steric	clashes	with	
the	MeCP2	peptide.	 Similarly,	D369	 is	 directly	 involved	 in	 binding	 to	MeCP2	peptide	 and	
mutation	of	an	aspartate	to	a	longer	glutamate	(D369E)	likely	clashes	with	K304MeCP2.	While	
the	Y446F	mutation	did	not	abolish	the	binding	of	MeCP2	to	TBL1XR1,	and	Y446A	mutation	
was	not	 tested,	 it	 is	possible	 that	Y446C	mutation	does	prevent	binding	as	 it	 is	unable	 to	
contribute	to	the	hydrophobic	binding	pocket	of	P302MeCP2.	
L282	and	A311	are	both	found	in	beta	strands.	The	mutation	of	either	of	those	residues	into	















is	 subject	 to	X-inactivation	 and	 therefore	 the	 female	patients	 are	mosaic	with	 some	 cells	
containing	wild-type	MeCP2	and	some	cells	containing	mutated	MeCP2.	Because	TBL1XR1	is	
autosomal,	such	mechanism	does	not	occur	and	mutations	in	the	gene	may	instead	cause	































mice	 bearing	 the	 minigene	 protein	 could	 be	 displaying	 mild	 RTT	 symptoms	 due	 to	 the	
disruption	 of	 the	 bridging	 function,	 which	 could	 happen	 for	 several	 reasons.	 First,	 the	




conserved	 linker	 region	 between	 MBD	 and	 NID	 was	 responsible	 for	 the	 phenotype	 by	
disrupting	a	reported	AT-hook	(amino	acids	265–272).	Finally,	further	research	performed	by	
Rebekah	Tillotson	showed	that	the	minigene	may	not	be	as	stable	as	wild	type	protein	in	vivo,	
as	 the	 protein	 levels	 were	 reduced	 by	 approximately	 50%	when	 compared	 to	 wild-type.	
However,	 the	 mRNA	 levels	 were	 approximately	 two	 times	 higher	 than	 that	 of	 wild-type	
MeCP2,	which	 could	mean	 there	 are	 issues	with	 translation.	 In	 either	 case	 the	minigene	
protein	could	be	functionally	similar	to	wild-type,	but	the	decreased	levels	of	the	protein	in	
cells	could	lead	to	the	mild	phenotype	seen.	
In	 this	 chapter	 the	 functionality	 of	 MBD	 and	 NID	 in	 the	 context	 of	 the	 minigene	 were	
examined.	Electrophoretic	mobility	shift	assays	(EMSAs)	were	conducted	to	see	whether	the	
MeCP2	minigene	protein	is	able	to	bind	to	both	DNA	and	TBL1XR1.	In	addition,	a	hypothesis	





possible	 that	 MeCP2	 displays	 similar	 effect	 by	 changing	 the	 affinity	 of	 the	 NID	 to	














protein	 in	 cells,	 the	 knock-in	 gene	 also	 contained	 a	 C-terminal	 EGFP	 tag,	 however	 in	 the	








non-specifically	 to	 the	bacterial	 genome	and	 interferes	with	normal	 cell	 function,	 causing	










of	 induction	period.	After	one	 to	 two	hours	post-induction,	 the	 cells	had	entered	growth	
arrest	as	evidenced	by	the	lack	of	increasing	OD600	value.	Further	samples	were	taken	every	
hour	until	the	cells	were	harvested.	Pulldowns	were	performed	on	all	the	induced	samples	










was	 10.2.	 Consequently,	 the	 initial	 proposed	 protocol	 included	 IMAC	 as	 the	 first	 step,	
followed	 by	 cation-exchange	 chromatography,	 and	 then	 finally	 size-exclusion	
chromatography	to	further	increase	the	purity	of	the	protein	as	well	as	to	verify	that	it	exists	
as	a	single	species.		
Following	cell	 lysis	and	clearing	of	 the	supernatant	 through	centrifugation,	 the	 lysate	was	
added	to	Ni2+-NTA	resin	to	bind	the	MeCP2	minigene	protein.	Because	it	was	not	known	how	







Figure	 6.4.1.	 Batch	 pulldown	 of	 MeCP2	 ‘minigene’	 protein	 using	 Ni2+NTA	 resin.	 The	 protein	 of	
interest	is	marked	with	black	arrow.	Elutions	were	done	by	increasing	the	concentration	of	imidazole	
by	100	mM	each	 time,	 starting	 from	100	mM	 in	E1,	and	ending	with	500	mM	 in	E5.	 S	–	Soluble	
fraction,	P	–	Pellet,	E1-E5	–	elution	1-5	
The	protein	was	relatively	pure,	however	there	were	some	contaminants	present	and	based	































Figure	 6.4.5.	 Size-exclusion	 chromatogram	 of	 MeCP2	 minigene	 using	 Superdex	 200	 10/300	 GL	
column.		
The	resulting	fractions	that	mostly	contained	the	putative	MeCP2	minigene	were	pooled	and	
subjected	 to	 size-exclusion	 chromatography.	 Some	of	 the	protein	 co-eluted	with	multiple	












To	 recover	more	of	 the	MeCP2	protein	at	high	purity,	 several	 changes	were	made	 to	 the	
purification	protocol.	First,	 the	salt	concentration	of	 the	elution	buffer	 in	cation-exchange	
step	was	reduced	from	1000	mM	to	500	mM.	This	allowed	the	use	the	same	length	gradient	
with	better	resolution	of	peaks.	In	addition,	after	binding	of	the	MeCP2	to	the	column,	the	


























Figure	 6.5.4.	 Size-exclusion	 chromatogram	 of	 MeCP2	 minigene	 using	 Superdex	 200	 10/300	 GL	
column.		
6.6 Biophysical	assays	
Unless	otherwise	stated,	 the	assays	 in	 this	section	were	carried	out	by	Ceitidh	Taylor	and	
Ciarán	Daly	under	my	supervision.	
6.6.1 Measuring	 the	 stability	 of	 the	 MeCP2	 minigene	 using	 thermal	
denaturation	assays	
To	assess	whether	the	MeCP2	minigene	was	stable	and	whether	it	had	tertiary	structure,	a	














of	 the	minigene	protein	 is	structured,	 the	melting	temperature	most	 likely	represents	the	
MBD	as	the	MBD	is	only	40%	unstructured	while	the	whole	TRD	(spanning	residues	198-305)	
is	reported	to	be	more	than	80%	unstructured,	based	on	circular	dichroism	analysis	(Adams	








using	 electrophoretic	 mobility	 shift	 assays	 (EMSA).	 This	 assay	 tracks	 the	 migration	 of	 a	
species	through	a	porous	medium,	with	the	migration	speed	being	dependent	on	the	size	of	
the	species.	Larger	species	move	more	slowly	through	the	medium	and	are	therefore	shifted	
to	a	 lesser	extent	 than	 smaller	 species.	As	 interacting	partners	are	added,	 the	 size	of	 the	
complex	increases	and	the	speed	of	migration	decreases.	








both	 the	 positive	 control	 (wild-type	MeCP2	MBD)	 and	 the	 negative	 (R111G	MBD)	 (both	
proteins	 received	 from	 Rebekah	 Tillotson)	 also	 bound	 the	 DNA,	 apparently	 to	 an	 equal	





Forward	sequence	 5’DY-681 - ATA GAA GAA TTC 5GT TCC AG  3’ 






Figure	 6.6.3.	 EMSA	 using	 8%	 acrylamide	 native	 gel	 to	 detect	 whether	 MeCP2	 minigene	 has	 a	
functional	MBD.	The	amount	of	labeled	DNA	was	0.5	µM	in	all	samples.		




























The	 initial	 EMSAs	 showed	 that	 there	 was	 binding	 of	 MeCP2	 minigene	 to	 DNA	 at	
concentrations	between	1.2	and	3.0	µM,	although	specific	binding	to	methylated	DNA	could	
not	be	established.	Nevertheless,	 the	effect	of	TBL1XR1	on	this	 interaction	was	examined		













majority	 of	 the	MeCP2-DNA-TBL1XR1	 being	 stuck	 in	 the	 wells.	 This	 could	 be	 due	 to	 the	

























































Another	 assay	 was	 set	 up	 to	 see	 how	 consistent	 the	 assay	 was	 between	 runs,	 and	 to	
understand	 the	 origin	 of	 the	 scattered	 light.	 The	 concentration	 of	 the	 probe	 was	 also	
increased	from	45.4	nM	to	100	nM	to	boost	the	fluorescence	signal	(Figure	6.6.9).	This	time	

















subtracted	 from	 the	 experimental	 values,	 the	micelles	might	 interfere	with	 the	 assay	 by	
sequestering	either	the	probe	or	the	protein	and	producing	erroneous	anisotropy	values.	
	
Figure	 6.6.10.	 Fluorescence	 anisotropy	 assay	 using	 Cy3-tagged	DNA	 probe	 (100	 nM)	with	 0.17%	
Tween	 20,	 and	 increasing	 concentration	 of	 MeCP2	 minigene	 protein.	 Excitation	 and	 emission	
wavelengths	were	530	nm	and	562	nm,	respectively.	All	experiments	were	done	in	triplicate.	Binding	
curve	was	fitted	using	non-linear	regression.	Error	bars	are	one	standard	deviation.	
The	assay	was	 repeated	using	Tween	20	below	 its	 critical	micelle	 concentration	 (CMC)	 to	
prevent	 the	 formation	 of	 micelles	 (Figure	 6.6.11).	 The	 graph	 showed	 that	 there	 was	 an	
increase	in	anisotropy	upon	the	addition	of	MeCP2	minigene	up	to	250	nM,	after	which	the	
anisotropy	started	dropping.	When	the	rata	data	was	examined,	 the	total	 intensity	of	 the	
measured	light	dropped	at	those	intensities	as	well.	This	indicated	that	there	was	quenching	
of	the	fluorophore	upon	binding	to	MeCP2	minigene.	In	fact,	in	Figure	6.6.8	and	Figure	6.6.9	
the	 same	effect	was	 seen	 to	a	 smaller	extent,	probably	masked	by	 the	 scattered	 light.	 In		
Figure	 6.6.8	 the	 effect	 was	 very	 small	 due	 to	 already	 high	 measured	 anisotropy	 values.	
However,	due	to	the	high	standard	deviation	values	in	Figure	6.6.9	the	quenching	was	not	
spotted	because	 it	was	 thought	 the	 intermediate	protein	concentration	anisotropy	values	


























Because	 knock-in	 mice	 containing	 MeCP2	 minigene	 protein	 showed	 a	 mild	 RTT-like	









The	 MeCP2	 minigene	 protein	 was	 expressed	 and	 purified	 from	 E.	 coli.	 Due	 to	 the	
promiscuous	nature	of	 the	MBD	DNA	binding,	 the	expression	protocol	was	adapted	 from	








To	assess	whether	 the	MBD	 is	 functional,	 several	EMSA	assays	were	set	up.	These	assays	




of	 MeCP2-DNA-TBL1XR1,	 was	 observed	 by	 EMSA.	 In	 the	 same	 assay,	 an	 increase	 in	 the	
affinity	of	MeCP2	to	DNA	was	indicated	as	lower	concentrations	of	MeCP2	in	the	presence	of	






likely	 makes	 this	 value	 erroneous.	 As	 the	 wells	 were	 observed	 to	 have	 a	 pronounced	
meniscus	upon	the	addition	of	MeCP2	protein,	a	non-ionic	detergent	(Tween	20)	was	added	
at	a	concentration	below	its	CMC.	This	lowered	the	measured	anisotropy	values	to	physically	

















insect	 cell	 expression	 system,	 the	 expression	 of	 various	 TBL1X	 and	 TBL1XR1	 constructs	
regularly	reached	4-5	mg	of	protein	per	20	g	of	wet	cell	pellet.	
Successful	 purification	 protocols	were	 established	 for	 TBL1X	 and	 TBL1XR1	WD40	 domain	
constructs.	 At	 first	 there	were	 issues	with	 these	 two	proteins	 during	 ion-exchange	 steps.	












were	 found	 to	be	 relatively	 thermostable,	with	melting	 temperatures	around	60˚C.	While	
testing	the	effect	of	different	cations	and	anions,	it	was	found	that	while	NaCl	did	not	affect	









After	 an	 initial	 sparse-matrix	 screening	 and	 subsequent	 optimisation	 of	 crystallisation	
conditions,	co-crystals	of	MeCP2	and	TBL1XR1	were	obtained.	While	the	grown	crystals	were	
stacked	plates,	 it	was	possible	to	separate	them	and	freeze	 individual	crystals,	or	 in	some	
cases	 stacked	 crystals	with	non-overlapping	parts.	 The	best	 diffraction	 set	 collected	 from	
these	crystals	was	at	2.5	Å.	The	structure	was	solved	using	molecular	replacement	using	a	
human	TBL1XR1	WD40	domain	as	 a	model.	 The	 structure	 showed	 that	 there	was	MeCP2	
peptide	present	bound	to	two	of	the	four	TBL1XR1	molecules	in	the	asymmetric	unit.	While	
























acids	 (aspartate	 to	 asparagine,	 glutamate	 to	 glutamine,	 tyrosine	 to	 phenylalanine)	 or	 to	
neutral	(alanine)	ones.	The	effects	of	these	mutations	were	assessed	using	surface	plasmon	
resonance	assays	to	measure	binding	constants.	True	to	the	predictions	made	based	on	the	
structure,	all	but	 two	of	 the	amino	acids,	when	mutated,	either	abolished	or	 reduced	the	
binding	MeCP2	 to	 TBL1XR1.	 The	 reduction	 in	 the	 binding	 constants	was	 large	 enough	 to	
abolish	 the	 interaction	 in	 a	 cellular	 context,	 as	 seen	 through	 the	 co-localisation	 assays	











that	 are	most	 important	 for	MeCP2	binding	 demonstrated	with	 high	 confidence	 that	 the	
main	function	of	MeCP2	is	to	bind	TBLR1,	that	NID	mutations	cause	the	loss	of	binding	to	
NCoR/SMRT,	and	that	this	is	sufficient	to	cause	RTT.	Furthermore,	this	also	casts	doubt	on	
the	 competing	 hypothesis	 that	 the	 primary	 function	 of	 the	 NID	 is	 to	 bind	 DNA,	 as	mice	
harbouring	TBLR1	mutations	that	abolish	MeCP2	binding	nevertheless	display	neurological	
symptoms,	 despite	 retaining	 wild-type	 MeCP2	 (Matthew	 Lyst,	 Jim	 Selfridge,	 personal	
communication).	Furthermore,	no	RTT	mutations	 that	 retain	 the	electropositive	nature	of	
the	NID	(such	as	K305R)	have	been	demonstrated	to	disrupt	the	NID	binding	to	DNA,	hinting	
at	 the	possibility	 that	 the	DNA	binding	 is	 non-specific	 owing	 to	 the	highly	 electropositive	
nature	of	 the	NID.	Taken	 together,	 the	data	presented	 in	 this	 thesis	 strongly	 support	 the	







As	the	 individual	WD40	proteins	are	able	to	bind	to	different	types	of	 ligands,	 there	 is	no	
defined	binding	pocket	or	motif	in	these	domains	between	different	structures	owing	to	the	
variable	 biochemical	 nature	 of	 their	 binders.	 Only	 the	 binding	 site	 locations	 are	 shared	




















The	 arginine	 is	 inserted	 into	 the	 central	 channel	 of	 the	WD40	 domain	 where	 it	 forms	 cation-π	
interactions	with	two	phenylalanines.	
In	the	case	of	MeCP2,	it	is	the	lysine	304	(K304)	that	is	inserted	into	the	central	channel	to	
form	hydrogen	bonds	and	salt	bridges	with	TBLR1.	 Interestingly,	 rather	 than	utilising	 side	
chains	of	the	WD40	domain	for	recognition,	like	for	example	MLL1	shown	above,	K304	binds	





in	 many	 other	 peptides	 (Figure	 7.3.3).	 It	 is	 unknown	 whether	 these	 bonds	 exist	 in	 the	
unbound	 state,	 however	 these	 interacting	 peptides	 are	 very	 often	 predicted	 to	 be	 in	
intrinsically	unstructured	regions.	 It	 is	therefore	 likely	that	they	help	the	peptides	adopt	a	





















before,	 binds	 histone	 H3	 with	 affinities	 between	 700	 nM	 and	 7	 μM,	 depending	 on	 the	
methylation	state	of	the	histone	(Nowak	et	al.,	2011).	However,	there	is	evidence	that	some	
peptides	 utilise	 multiple	 similar	 binding	 sites	 to	 enhance	 binding	 to	WD40	 domains,	 for	









TBLR1	 WD40	 domain,	 or	 to	 an	 adjacent	 WD40	 domain	 in	 the	 context	 of	 a	 complete	






appear	to	be	an	obvious	binding	pocket	as	the	side	 is	relatively	 flat	 (Figure	7.3.5A).	There	













face.	Even	 the	 location	of	 the	binding	site	around	the	circumference	 is	different	between	














Table	 7.3.1.	 Examples	 of	 proteins	 found	 by	MOTIF2	 that	 contain	 a	motif	 similar	 to	MeCP2	NID.	
Protein	 roles	are	described	as	according	 to	UniProt,	prediction	about	motif	disorder	 is	based	on	
DisEmbl	algorithm.	

























them	 are	 involved	 in	 transcriptional	 regulation	 and	 histone	modification	 (Table	 7.3.1).	 In	
addition,	these	motifs	tend	to	be	positioned	in	intrinsically	disordered	regions,	a	factor	that	
is	likely	to	be	required	for	binding	to	TBLR1.	Given	the	role	of	TBLR1	in	cells,	it	is	possible	that	
there	 are	 other	 low-affinity	 binders	 that	 compete	 for	 binding	 with	 MeCP2	 to	 carefully	
regulate	transcription.	
7.4 The	 role	 of	 MeCP2	 in	 recruiting	 TBL1X/TBL1XR1	 was	
investigated	
While	MeCP2	 is	 a	 highly	 conserved	 protein	 among	 vertebrates,	 the	 majority	 of	 the	 RTT	

















8.1 Screening	 for	 small-drug	 like	 compounds	 to	 inhibit	 or	
facilitate	MeCP2-TBLR1	interaction	
Data	from	experiments	done	in	mice	suggests	that	RTT	may	be	treatable	in	humans,	if	the	
mutated	 protein	 could	 be	 made	 to	 bind	 TBL1	 or	 TBLR1	 more	 tightly.	 Similarly,	 MeCP2	
overexpression	 syndrome	 should	 be	 amenable	 to	 treatment	 by	 disrupting	 MeCP2-
TBL1/TBLR1	 interaction.	 In	 either	 case,	 small	 drug-like	 molecules	 represent	 a	 potential	
avenue	to	explore	owing	to	the	abundance	of	drug-like	molecule	libraries.	





domain	 central	 channel	 through	 a	 combination	 of	 hydrophobic	 interactions	 and	 water-





RTT	mutations	bind	 to	 the	TBLR1	WD40	domain	and	 therefore	 treat	RTT.	 	For	example,	a	
small	drug-like	molecule	could	bind	in	the	space	left	by	the	R306C	RTT	mutation.	A	compound	







could	 facilitate	 the	binding	of	other	RTT	mutations	by	 facilitating	new	binding	modes	 (for	








needs	 to	 produce	 a	 signal	 (or	 an	 absence	 of	 a	 signal)	 whenever	 such	 interaction	 occurs	
between	the	compound	and	 its	 target.	A	variety	of	biochemical	assays	 fulfil	 this	criterion.	
However,	for	the	purpose	of	drug	development	a	number	of	constraints	are	introduced,	such	
as	scalability,	speed	of	setting	up,	and	fast	readouts.	
Of	 the	 assays	 used	 during	 this	 project,	 both	 fluorescence	 anisotropy	 and	 thermal	
denaturation	assays	could	be	used	to	screen	these	compounds.	In	the	case	of	former,	binding	
of	 a	 fluorescent	 MeCP2	 peptide	 to	 TBLR1	 WD40	 domain	 in	 the	 presence	 of	 increasing	
concentrations	of	a	compound	would	reveal	whether	it	could	compete	MeCP2	off	TBLR1	and	
therefore	act	as	an	inhibitor.	Alternatively,	competing	fluorescently	labelled	MeCP2	peptide	
off	with	a	non-fluorescent	peptide	 in	 the	presence	of	 compounds	would	 show	whether	a	










assay	 (Turconi	 et	 al.,	 2001).	 The	 other	 assay	 utilised	 extensively	 during	 project,	 thermal	
denaturation	 assay,	 requires	 less	 protein	 owing	 to	 both	 lower	 concentration	 and	 volume	
requirement	(2	μM,	50	μl).	Even	then,	screening	of	a	large	number	of	compounds	is	time-
consuming	unless	robotics	can	be	utilised	to	do	the	pipetting.	A	drawback	of	this	assay	is	that	
the	 (de)stabilisation	 of	 the	 target	 is	 an	 indirect	 readout	 for	 binding,	 and	 accurate	
determination	of	KD	values	is	difficult	(Lo	et	al.,	2004).	Therefore,	this	assay	is	more	suitable	





AlphaLISA	 is	 a	 high-throughput	 assay	 that	 could	 also	 be	 implemented	 for	 compound	
screening.	The	principle	of	the	assay	is	to	bring	two	beads	(donor	and	acceptor)	coated	in	
antibodies	against	the	protein(s)	of	interest	into	proximity.	Illuminating	the	donor	beads	with	




Figure	 8.1.1.	 Principle	 of	 AlphaLISA	 assay.	 Two	 proteins,	 in	 our	 case	 TBLR1	 (blue)	 and	 MeCP2	
(orange)	are	bound	to	acceptor	and	donor	beads	via	antibodies	that	have	been	attached	to	these	
beads.	 If	 the	 two	 beads	 are	 less	 than	 200	 nm	 apart,	 i.e.	 a	 binding	 event	 has	 occurred,	 then	
illumination	 of	 the	 donor	 bead	 with	 a	 wavelength	 of	 680nm	 produces	 a	 singlet	 oxygen	 which	
initiates	a	cascade	of	chemical	reactions	in	the	acceptor	bead,	leading	to	chemiluminescence	at	618	
nm	that	can	be	detected.	
Variations	 of	 this	 assay	 exist,	 for	 example	 AlphaScreen	 which	 uses	 a	 slightly	 different	
chemical	 for	 light	 production,	 and	which	 does	 not	 require	 specific	 antibodies	 against	 the	





of	 compounds.	 This	 assay	 could	 detect	 either	 inhibitors	 of	 wild-type	 MeCP2-TBLR1	 or	
activators	of	mutant	MeCP2-TBLR1	interaction.	The	advantages	of	this	type	of	screen	are	high	
sensitivity,	 high	 signal	 to	 background	 ratio,	 easy	miniaturization,	 as	well	 as	 being	 able	 to	
perform	 this	 assay	 on	 crude	 cell	 lysates.	 In	 the	 case	 of	 AlphaLISA,	 a	 drawback	 is	 the	
requirement	for	specific	antibodies	towards	the	interaction	partners,	which	can	be	costly.	
The	main	drawback	of	most	in	vitro	assays	in	high-throughput	screening	is	the	requirement	
































localised	 in	 the	 cytoplasm	 upon	 the	 loss	 of	 MeCP2-TBL1	 interaction.	 By	 looking	 at	 the	






cost	 of	 drug	development.	Due	 to	 the	 availability	 of	 the	 TBLR1	 crystal	 structure	with	 the	
bound	peptide,	 it	 is	possible	 to	use	 structure-based	virtual	 screening	 to	define	 the	 ligand	
binding	site	on	TBLR1,	and	dock	chemical	compound	libraries	using	specialised	software	to	
find	potential	activators/inhibitors.	In	addition,	it	 is	possible	to	use	the	bound	MeCP2	as	a	





There	are	currently	 several	different	approaches	being	developed	 to	 treat	RTT	by	various	
groups.	One	of	 these	approaches	 is	 seeking	 to	reintroduce	a	 functional	copy	of	MeCP2	 in	
patients	who	carry	RTT	mutations.	It	has	been	shown	that	it	is	possible	to	deliver	a	copy	of	
the	MeCP2	 gene	 into	 null	 male	 mice	 using	 recombinant	 adeno-associated	 virus	 vectors,	























aminoglycosides	which	 are	 highly	 toxic,	 although	 newer,	 less-toxic	 alternatives	 are	 being	






have	 limited	 side-effects,	 ideally	 be	 orally	 bioavailable,	 and	 most	 importantly	 have	
appropriate	 kinetics	 so	 that	 the	NCoR/SMRT	 complex	 is	 still	 able	 to	 respond	 to	 neuronal	
stimuli	 and	 not	 lock	 it	 in	 a	 state	 of	 constant	 activity/inactivity.	 However,	 small	 drug-like	
molecules	can	be	easily	titrated,	ameliorating	issues	with	dosage	that	plague	some	of	these	
other	 treatment	options.	 In	 this	 light	 these	different	approaches	should	not	be	viewed	as	






313	peptide	had	a	 slightly	higher	affinity	 for	TBL1XR1	WD40	domain	 than	 the	MeCP2285-309	
peptide.	While	the	amino	acids	seen	in	the	crystal	structure	are	likely	to	be	the	main	binding	






the	 NCoR/SMRT	 complex,	 such	 as	 NCoR/SMRT	 or	 HDAC3.	 A	 further	 question	 is	 the	









that	MeCP2	 has	 a	 basic	 region	 (including	 the	 residues	 seen	 in	 the	 crystal	 structure)	 that	
interacts	with	DNA,	and	that	mutations	in	the	NID	cause	RTT	by	abolishing	the	interaction	of	
MeCP2	with	DNA.	However,	 in	the	 light	of	the	co-crystal	structure	where	all	 four	NID	RTT	
mutations	are	seen	making	extensive	contacts	with	TBL1XR1,	it	is	more	likely	that	the	loss	of	
binding	of	MeCP2	to	TBL1XR1	is	causative	of	RTT	in	the	case	of	NID	mutations.	Demonstrating	
that	 these	novel	mutations	abolish	 the	 interaction	with	MeCP2	would	be	the	 first	 step	to	
elucidating	their	role	in	these	diseases.	In	addition,	if	mice	bearing	any	of	the	TBL1XR1	(or	
TBL1X)	mutations	that	cause	the	loss	of	binding	of	MeCP2	were	to	show	RTT	phenotype,	it	




WD40	 domains	 are	 common	 scaffolds	 for	 protein-protein	 interactions	 through	 their	 top,	
bottom	and	side	faces.	It	is	entirely	possible	that	the	interaction	with	MeCP2	is	not	the	only	
function	 of	 these	 WD40	 domains.	 Indeed,	 there	 are	 patients	 diagnosed	 with	 a	 RTT-like	
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10 		Appendix	
10.1 		TBL1XR1	and	MeCP2	SPR	data	
	
Figure	10.1.1	Wild-type	TBL1XR1	with	MeCP2	285-313	peptide	
	
Figure	10.1.2.	Wild-type	TBL1XR1	with	MeCP2	285-309	peptide	
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Figure	10.1.3.	Wild-type	TBL1XR1	with	MeCP2	285-313	R306C	peptide	
	
Figure	10.1.4.	TBL1XR1	E171A	with	MeCP2	285-313	peptide	
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Figure	10.1.5.	TBL1XR1	E171A	with	MeCP2	285-309	peptide	
	
Figure	10.1.6.	TBL1XR1	E171A	with	MeCP2	285-313	R306C	peptide	
10.	Appendix	
173	
	
	
Figure	10.1.7.	TBL1XR1	E171Q	with	MeCP2	285-313	peptide	
	
Figure	10.1.8.	TBL1XR1	E171Q	with	MeCP2	285-309	peptide	
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Figure	10.1.9.	TBL1XR1	E171Q	with	MeCP2	285-313	R306C	peptide	
	
Figure	10.1.10.	TBL1XR1	C214S	with	MeCP2	285-313	peptide	
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Figure	10.1.11.	TBL1XR1	C214S	with	MeCP2	285-309	peptide	
	
Figure	10.1.12.	TBL1XR1	C214S	with	MeCP2	285-313	R306C	peptide	
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Figure	10.1.13.	TBL1XR1	D313N	with	MeCP2	285-313	peptide	
	
Figure	10.1.14.	TBL1XR1	D313N	with	MeCP2	285-309	peptide	
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Figure	10.1.15.	TBL1XR1	D313N	with	MeCP2	285-313	R306C	peptide	
	
	
Figure	10.1.16.	TBL1XR1	E351A	with	MeCP2	285-313	peptide	
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Figure	10.1.17.	TBL1XR1	E351A	with	MeCP2	285-309	peptide	
	
Figure	10.1.18.	TBL1XR1	E351A	with	MeCP2	285-313	R306C	peptide	
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Figure	10.1.19.	TBL1XR1	E351D	with	MeCP2	285-313	peptide	
	
Figure	10.1.20.	TBL1XR1	E351D	with	MeCP2	285-309	peptide	
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Figure	10.1.21.	TBL1XR1	E351D	with	MeCP2	285-313	R306C	peptide	
	
Figure	10.1.22.	TBL1XR1	D369A	with	MeCP2	285-313	peptide	
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Figure	10.1.23.	TBL1XR1	D369A	with	MeCP2	285-309	peptide	
	
Figure	10.1.24.	TBL1XR1	D369A	with	MeCP2	285-313	R306C	peptide	
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Figure	10.1.25.	TBL1XR1	Y446F	with	MeCP2	285-313	peptide	
	
Figure	10.1.26.	TBL1XR1	Y446F	with	MeCP2	285-309	peptide	
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Figure	10.1.27.	TBL1XR1	Y446F	with	MeCP2	285-313	R306C	peptide	
	
	
	
	
